Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine or azacitidine plus IA versus IA induction in newly diagnosed young acute myeloid leukemia
ChiCTR2000036086Phase 3Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of decitabine, azacitidine, idarubicin and cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: 2-year overall survival rate. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
decitabineazacitidineidarubicincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2000036086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036086.